NASDAQ: HALO · Biotechnology
Halozyme Therapeutics (HALO) fair value and price range
As of 31 Oct 2026, Faircurve's model values Halozyme Therapeutics (HALO) at $134.12 a share. The stock last closed at $122.96, which puts the model's fair value 9.1% above the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 5 Nov 2026. Halozyme Therapeutics, Inc.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 31 Oct 2026 moved the fair value from $120.65 to $134.12 (+11.2%). The model changed its method this week; the move is not broken down.
What the model makes of itThe price of $122.96 is 9.1% below it. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What's nextNext report on 16 Feb 2027. Options prices imply a move of about 20% either way over the next month. On the model's Quality Momentum list since 28 Oct 2026 (a strategy with a proving record). The next weekly run is on Saturday 7 Nov 2026.
What price range does the model give HALO?
The calibrated range for HALO over 63 trading days is $99.60 to $159.29. It sits around the last close, and its width comes from the volatility that HALO's own options imply (71% a year), calibrated weekly against realised prices (n = 6,661 past valuations, refreshed 31 Oct 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $86.00 to $199.25. In 52% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 31 Oct 2026
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California. It operates in the United States, Switzerland, Ireland, Belgium, Japan and other international markets.
Faircurve's model puts the fair value at $134.12 a share, the midpoint of 2,000 simulations, on 31 Oct 2026. The previous run, on 24 Oct 2026, gave $120.65, so the fair value moved +11.2%. The model changed its method this week, and the move is not broken down. The calibrated range over 63 trading days is $112.87 to $151.01. Ranges built this way held the price 60% of the time at this horizon, based on 6,661 past valuations. The model grades the evidence as low, so no verdict is shown. The grade reflects how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.
Halozyme scores 82 out of 100 on the model's quality composite, measured against comparable companies. Earnings quality and growth quality both score 100, with trailing revenue growth of 37.6% against a peer median of 21.2%. Capital discipline scores 88. Stability scores 32, with EBITDA margin downside volatility over five years at 6.0 pts against a peer median of 5.6 pts. The model compares the company with Neurocrine Biosciences, Exelixis, Bio-Techne, BioMarin and Krystal Biotech, each of which has its own fair value on the site.
Written from the figures on this page for the 31 Oct 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does HALO report earnings, and how has the stock reacted?
Halozyme Therapeutics's next earnings report is scheduled for 16 Feb 2027. Companies can move their dates.
Options prices on 5 Nov 2026 imply a move of about 16.3% in either direction through the nearest expiry, about 14 days out. That is the size the market is pricing, not a direction. HALO's 30 day implied volatility works out to about 20.5% over one month.
On 5 Nov 2026 HALO moved 5.7% in one session, against the 2.8% a day that options had priced: 2.0 times the implied size, around an earnings report.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across HALO's last 8 reports, ignoring direction, was 6.1%.
What the options market has priced for a month's move in HALO
How does HALO score on business quality?
Halozyme Therapeutics's overall quality score is 82 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 83 | 31.0%ROIC | 39.2% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 100 | 1.95xFCF / net income | 1.08x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 100 | 37.6%Revenue growth, trailing | 21.2% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 88 | 2.5%Net buybacks / market value | 1.1% |
| Balance sheetNet debt to EBITDA and interest coverage. | 45 | 2.76xNet debt / EBITDA | -0.45x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 32 | 6.0 ptsEBITDA margin downside volatility, 5y | 5.6 pts |
How does HALO compare with similar companies?
The companies in biotechnology closest to Halozyme Therapeutics in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| NBIX Neurocrine Biosciences, Inc. | $159.76 | $162.09 | +1.5% | Fairly valued |
| JAZZ Jazz Pharmaceuticals plc | $227.32 | $256.45 | +12.8% | Low evidence grade |
| EXEL Exelixis, Inc. | $68.71 | $68.28 | -0.6% | Fairly valued |
| TECH Bio-Techne Corporation | $72.66 | $64.91 | -10.7% | Fairly valued |
| BMRN BioMarin Pharmaceutical Inc. | $56.12 | $70.40 | +25.4% | Undervalued |
| ALNY Alnylam Pharmaceuticals, Inc. | $156.66 | $165.50 | +5.6% | Low evidence grade |
| KRYS Krystal Biotech, Inc. | $300.25 | $384.08 | +27.9% | Undervalued |
| PTGX Protagonist Therapeutics, Inc. | $135.26 | $167.40 | +23.8% | Low evidence grade |
What the comparable companies' multiples alone would give for HALO, the peer-implied price, is $145.44 a share on this run. The fair value weighs that against the company's own multiple.
Halozyme Therapeutics at a glance
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets.
- Market value
- $14.9B
- Sector
- Healthcare
- Industry
- Biotechnology
- Revenue expected, next twelve months
- $2.1B
- Consensus revenue growth, next fiscal year
- +34.7%
- Analysts with estimates
- 5
- Beta to the US market
- 0.38
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Halozyme Therapeutics on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 24 Oct 2026 the model's fair value for HALO was $120.65. As of 31 Oct 2026 it is $134.12, a change of +11.2%. The model changed its method this week; the move is not broken down. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Halozyme Therapeutics's valuation
Is Halozyme Therapeutics stock undervalued or overvalued?
Faircurve's model puts HALO's fair value at $134.12 a share against a last close of $122.96, as of 31 Oct 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is HALO's fair value?
$134.12 a share as of 31 Oct 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $86.00 to $199.25.
What price range does the model give HALO?
$99.60 to $159.29 over 63 trading days. Ranges built this way held the price 60% of the time across 6,661 past valuations, refreshed 31 Oct 2026.
When does Halozyme Therapeutics report earnings next?
The next report is scheduled for 16 Feb 2027. Companies can move their dates.
How much has HALO moved on past earnings reports?
Across its last 8 reports the median two session move was 6.1%, ignoring direction. The largest was +23.4% around the report of 6 Aug 2026.
How confident is the model in this valuation?
The model's evidence grade for HALO is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on HALO
The model has an idea open on HALO under Quality Momentum since 28 Oct 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on HALO with their outcomes. A free account is enough.